Conference Contributions 2009
Kresken M, Leitner E, Seifert H, Körber-Irrgang B, Peters G, von Eiff C for the Study Group. Susceptibility of bacterial isolates to tigecycline after the introduction of this Glycylcycline in Germany: Results of a second multicentre surveillance trial.
49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, September 12-15, 2009: Abstract #C2-1955.
Kresken M, Hafner D. Susceptibility of Gram-positive pathogens to Linezolid and other antibacterial agents in Germany, 2001-2007. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, September 12-15, 2009: Abstract #C2-150.
Körber-Irrgang B, Kresken M, Wetzstein H-G. pH-Dependence of the activity of Pradofloxacin and four structual analogs against Escherichia coli and Staphylococcus aureus. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, September 12-15, 2009: Abstract #E-1967.
Kresken M, Körber-Irrgang B, Peters G, Leitner E, von Eiff C. Trends of antimicrobial resistance among Staphylococci and Enterococci in Germany. 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 16-19, 2009: P1075. Clin Microbiol Infect 2009;15(issue s4):S286.
Mutters R, Heizmann WR, Körber-Irrgang B, Leitner E, Kresken M. Comparative in vitro activity of tigecycline against pathogens obtained from intensive care patients in Germany. 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 16-19, 2009: P1612. Clin Microbiol Infect 2009;15(issue s4):S457-8.
Körber-Irrgang B, Kresken M. In-vitro activity of daptomycin combined with other antimicrobial agents against Gram-positive cocci. 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 16-19, 2009: P1627. Clin Microbiol Infect 2009;15(issue s4):S462.
Körber-Irrgang B, Kresken M. In-vitro activity of daptomycin combined with other antimicrobial agents against Gram-positive cocci. 61st Annual Meeting of DGHM, Göttingen, Deutschland, September 20-23, 2009: PRP27.
Kresken M, Leitner E, Seifert H, Körber-Irrgang B, Peters G, von Eiff C for the Study Group. In-vitro activity of tigecycline and comparators: a multicentre surveillance trial after the introduction of this glycylcycline in Germany. 61st Annual Meeting of DGHM, Göttingen, Deutschland, September 20-23, 2009.
Conference Contributions 2008
Seifert H, Leitner E, Körber-Irrgang B, Kresken M. Comparative in vitro activity of tigecycline against clinical isolates of the Acinetobacter baumannii group: Results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Program, 2005-2007. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / 46th Annual Meeting of the Infectious Diseases Society of America, Washington DC, USA, October 25-28, 2008: Abstract #C2-3870.
Dahmen V, Georgieva L, Körber-Irrgang B, Kresken M, Bauernfeind A, Schneider I
Prevalence and molecular relatedness of Extended-Spectrum Beta-Lactamases (ESBL) produced by Escherichia coli isolated from hospitalized patients in Germany. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / 46th Annual Meeting of the Infectious Diseases Society of America, Washington DC, USA, October 25-28, 2008: Abstract #C2-3884.
Kresken M, Körber-Irrgang B, Labischinski H, Stubbings W. Effect of pH on the in vitro activity of finafloxacin against Gram-negative and Gram-positive bacteria. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / 46th Annual Meeting of the Infectious Diseases Society of America, Washington DC, USA, October 25-28, 2008: Abstract #F1-2037.
Kresken M, Brauers J, Strommenger B, Witte W. Spread of MRSA clones in German hospitals and in vitro activity of tigecycline. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 19-22, 2008: P1433. Clin Microbiol Infect 2008;14(issue s7):S409-10.
Kresken M, Brauers J. German surveillance study on the in vitro activity of daptomycin against Gram-positive cocci. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 19-22, 2008: P1723. Clin Microbiol Infect 2008;14(issue s7):S500-1.
Kresken M, Brauers J, Knips L, Leitner E, Menke A, Walter S, Weiher H. Spread of tetracycline resistance genes among German isolates of Escherichia coli, Enterobacter cloacae, and Klebsiella pneumoniae and susceptibility to tigecycline. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 19-22, 2008: P2038. Clin Microbiol Infect 2008;14(issue s7):S599-600.
Kresken M, Brauers J, Körber-Irrgang B. Resistance among isolates of Haemophilus influenzae to orally administered b-lactams and fluoroquinolones: results of a nationwide surveillance study in Germany, winter 2007. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 19-22, 2008: P2054. Clin Microbiol Infect 2008;14(issue s7):S604-5.
Conference Contributions 2007
Kresken M, Brauers J, Körber-Irrgang B. In-vitro-activity of fosfomycin against fluoroquinolone-resistant or extended-spectrum beta-lactamase-producing isolates of Escherichia coli. Int J Med Microbiol 2007;297(s1):39.
Kresken M, Bagel S, Körber-Irrgang B, Wetzstein HG. Comparative study on the pharmacodynamics of pradofloxacin (PRA) and marbofloxacin (MAR) against Staphylococcus intermedius in an In Vitro Pharmacokinetic Model of Infection (IVPM)
47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20, 2007: Abstract #A-18.
Kresken M, Brauers J, Körber-Irrgang B, Menke A, Romfeld C. In vitro activities of ceftobiprole (BPR) combined with amikacin (AMK) or levofloxacin (LVX) against Pseudomonas aeruginosa (PA) by time kill methodology. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20, 2007: Abstract #E-273.
Kresken M, Brauers J, Prezelj A. In vitro activity of LK-157, a novel tricyclic carbapenem beta-lactamase inhibitor. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20, 2007: Abstract #F1-338.
Kresken M, Brauers J, Körber-Irrgang B, Labischinski H, Pelzer S. Comparative in vitro activities of the novel antibacterial friulimicin and other antibacterial agents against selected aerobic Gram-positive bacteria. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20, 2007: Abstract #F1-1642.
Kresken M, Brauers J, Halle E, Geiss H, Leitner E, Peters G, Seifert H. Comparative in vitro activity of tigecycline against ICU- and non-ICU isolates of five clinically important Gram-negative pathogens: results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Programme 2005. 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 - April 3, 2007: P666. Clin Microbiol Infect 2007;13(issue s1):S158-9.
Kresken M, Brauers J, Halle E, Geiss H, Leitner E, Peters G, Seifert H. In vitro activity of tigecycline against Gram-positive and Gram-negative bacteria cultured from blood samples, wound swabs and intra-abdominal specimens: results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Programme 2005. 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 - April 3, 2007: P1811. Clin Microbiol Infect 2007;13(issue s1):S517.
Kresken M, Brauers J. Susceptibility of Gram-positive pathogens to daptomycin and other antimicrobial agents: first results from the DAPTOGERM Surveillance Study. 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 - April 3, 2007: P1830. Clin Microbiol Infect 2007;13(issue s1):S523-4.
Kresken M, Brauers J, Halle E, Geiss H, Leitner E, Peters G, Seifert H. Comparative in vitro activity of tigecycline against staphylococci and enterococci from patients on ICU- and non-ICU wards: results of the German T.E.S.T. Surveillance Programme 2005. 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 - April 3, 2007: P1831. Clin Microbiol Infect 2007;13(issue s1):S524.
Conference Contributions 2006
Kresken M, Hafner D on behalf of the Working Group Antimicrobial Resistance of the Paul Ehrlich Society for Chemotherapy. Further increase of fluoroquinolone resistance among Escherichia coli isolates in a Central European Area. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 1-4, 2006: P1396. Clin Microbiol Infect 2006;12(issue s4).
Brauers J, Kresken M, Bagel S. Comparative in vitro activities of telavancin and other antibacterial agents against selected Gram-positive bacteria. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 1-4, 2006: P1582. Clin Microbiol Infect 2006;12(issue s4).
Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I. Evaluation of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium utilizing in-vitro time-kill methodology. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 1-4, 2006: P1583. Clin Microbiol Infect 2006;12(issue s4).
Kresken M, Hafner D. Working Group for Antimicrobial Resistance of the Paul Ehrlich Society for Chemotherapy. Susceptibilities of most prevalent Enterobacteriaceae species to ceftobiprole: results of the Antimicrobial Resistance Surveillance Study of the Paul Ehrlich Society for Chemotherapy, 2004. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27-30, 2006: Abstract #E-117.
Kresken M, Brauers J. In vitro activity of the novel antibacterial MCB3681 against selected Gram-positive and -negative bacteria compared to established antibiotics.
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27-30, 2006: Abstract #F1-1967.
Seifert H, Brauers J, Leitner E, Kresken M. Comparative in vitro activity of tigecycline against clinical Acinetobacter baumannii and Stenotrophomonas maltophilia isolates: results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Program 2005
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27-30, 2006: Abstract #E-748.
Kresken M, Brauers J, Peters G, Leitner E. Susceptibilities of three staphylococcal species to tigecycline and other drugs: results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Program 2005.46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27-30, 2006: Abstract #E-751.
Geiss HK, Halle E, Brauers J, Leitner E, Kresken M. In vitro activity of tigecycline against clinical isolates of Escherichia coli and four other major Enterobacteriaceae species: results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Program 2005
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27-30, 2006: Abstract #E-752.
Conference Contributions 2005
Kresken M, Hafner D on behalf of the Working Group Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Increase of resistance to nalidixic acid among four clinically important Enterobacteriaceae pathogens in three Central European countries. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005: P1464. Clin Microbiol Infect 2005;11(issue s2):S474.
Kresken M, Heep M. In vitro activity of ceftobiprole in combination with ciprofloxacin, levofloxacin, amikacin, and tobramycin against clinical isolates of Pseudomonas aeruginosa. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, December 16-19, 2005: Abstract #E-311.
Conference Contributions 2004
Kresken M, Heep M, Hafner D. In-vitro activities of ceftobiprole (BAL9141), the active component of ceftobiprole (BAL5788), and seven other beta-lactams against selected strains of Pseudomonas aeruginosa susceptible or resistant to ceftazidime. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, October 30 - November 2, 2004: Abstract #E-2022.
Kresken M, Heep M, Wiegand I. Gram-negative bacteria producing characterized beta-lactamases: in vitro activities of BAL 9141, the active component of prodrug BAL 5788, and comparators. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004: P536. Clin Microbiol Infect 2004;10(issue s3):S120-1.
Kresken M, Hafner D, Allerberger F, Seifert H on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Susceptibilities of clinical Acinetobacter baumannii and Stenotrophomonas maltophilia isolates to 14 antimicrobial agents: Results of the Antimicrobial Resistance Surveillance Study of the Paul Ehrlich Society for Chemotherapy, 2001. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004: P1118. Clin Microbiol Infect 2004;10(issue s3):S304.
Henrichfreise B, Bagel S, Kresken M, Sherwood K, Wiedemann B. Detection of internationally spread multiresistant Streptococcus pneumoniae clones in Germany using Multilocus Sequence Typing. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004: P1131. Clin Microbiol Infect 2004;10(issue s3):S308.
Kresken M, Heep M. In vitro activities of BAL9141, the active component of prodrug BAL5788, and seven other beta-lactam antimicrobial agents towards clinical isolates of 12 members of the family Enterobacteriaceae. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004: P1209. Clin Microbiol Infect 2004;10(issue s3):S334.
Wiedemann B, Kresken M, Bagel S. Prevention of resistance development with Levofloxacin in epithelial lining fluid demonstrated by simulation of the concentration time curves in an in vitro model. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004: P1808. Clin Microbiol Infect 2004;10(issue s3):S516.
Conference Contributions 2003
Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA. Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Prevalence of resistance to fluoroquinolones (ciprofloxacin) in clinical isolates of Escherichia coli in Germany, 1990-2001. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA, September 14-17, 2003: Abstract #C2-96.
Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA. Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Susceptibility of Pseudomonas aeruginosa to antimicrobial agents in Germany, 2001. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA, September 14-17, 2003: Abstract #C2-1961.
Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Prevalence of mupirocin resistance in isolates of Staphylococcus aureus and Staphylococcus epidermidis in three Central European countries: Results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy 2001. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P1448. Clin Microbiol Infect 2003;9(issue s1):S352.
Brauers J, Kresken M, Shah PM on behalf of the German Linezolid Resistance Study Group. Surveillance of linezolid resistance in Germany. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P1445. Clin Microbiol Infect 2003;9(issue s1):S351.
Brauers J, Pfruender D, Kresken M. Interpretive breakpoints for susceptibility testing of bacteria against penicillin G/sulbactam in the disk diffusion test according to the German DIN Standard 58940. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P473. Clin Microbiol Infect 2003;9(issue s1):S91.
Henrichfreise B, Wiedemann B, Bagel S, Brauers J, Kresken M. High prevalence of multiresistant penicillin-intermediate Streptococcus pneumoniae due to clonal spread in Germany, winter 2000/01. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P1055. Clin Microbiol Infect 2003;9(issue s1):S247.
Kresken M, Brauers J, Bagel S. Surveillance of antimicobial resistance in four major pathogens of community-acquired respiratory tract infections in Germany, 2002. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P1575. Clin Microbiol Infect 2003;9(issue s1):S384-5.
Bagel S, Brauers J, Kresken M. Time-kill kinetics of clarithromycin, roxithromycin, and azithromycin against selected Streptococcus pneumoniae isolates compared with those of penicillin and moxifloxacin. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P1013. Clin Microbiol Infect 2003;9(issue s1):S236.
Kresken M, Brauers J, Bagel S, Henrichfreise B. Was wissen wir über die Makrolidresistenz bei Streptococcus pneumoniae in Deutschland? Infection 2003;31(issue s1):86.
Brauers J, Bagel S, Kresken M. In-Vitro-Aktivität von Telithromycin und anderen Antibiotika gegenüber Streptococcus pneumoniae, Haemophilus influenzae und Moraxella catarrhalis in Deutschland. Infection 2003;31(issue s1):81.
Conference Contributions 2002
Bagel S, Brauers J, Kresken M. In vitro activity of ABT-773 and six other antibacterial agents against recent community-acquired respiratory tract isolates: A German Multicenter Study. ICMAS-KO 6, Bologna, Italy, January 23-25: Abstract #2.11.
Kresken M, Bagel S, Brauers J, Machka K. In vitro activities of gemifloxacin and four other fluoroquinolones against contemporary respiratory tract pathogens recovered from outpatients in Germany. 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, April 24-27, 2002: P1114. Clin Microbiol Infect 2002;8(issue s1):S252.
Kresken M, Bagel S, Brauers J. Comparative in vitro activity of faropenem, a new oral penem, against recent respiratory tract isolates recovered from outpatients in Germany. 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, April 24-27, 2002:P1388. Clin Microbiol Infect 2002;8(issue s1):S326.
Bagel S, Kresken M, Schmalreck A, Beck G, Pfründer D. In vitro activity of new sulbactam combinations against aerobic and anaerobic bacteria: results of a German Multicentre Study. 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, April 24-27, 2002: P1439. Clin Microbiol Infect 2002;8(issue s1):S340.
Henrichfreise B, Wiedemann B, Bagel S, Brauers J, Kresken M. Geographical variation of macrolide-resistance in S. pneumoniae isolates from Germany. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA, September 27-30, 2002: Abstract #C2-1979.
Brauers J, Bagel S, Kresken M. In vitro activity of telithromycin and other antibacterial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Germany. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA, September 27-30, 2002: Abstract #E-1896.
Kresken M, Bagel S, Brauers J, Henrichfreise B. In vitro activity of the ketolide ABT-773 against macrolide-susceptible and -resistant isolates of Streptococcus pneumoniae in Germany. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA, September 27-30, 2002: Abstract #E-1897.
Conference Contributions 2001
Bagel S, Brauers J, Kresken M. In vitro activity of ABT-773 and six other antibacterial agents against recent community-acquired respiratory tract isolates: A German Multicenter Study. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA, September and December 2001: Abstract #1007.